Search Results - "Astori, C"

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms by Pietra, D, Rumi, E, Ferretti, V V, Buduo, C A Di, Milanesi, C, Cavalloni, C, Sant'Antonio, E, Abbonante, V, Moccia, F, Casetti, I C, Bellini, M, Renna, M C, Roncoroni, E, Fugazza, E, Astori, C, Boveri, E, Rosti, V, Barosi, G, Balduini, A, Cazzola, M

“…A quarter of patients with essential thrombocythemia or primary myelofibrosis carry a driver mutation of CALR , the calreticulin gene. A 52-bp deletion (type…”
Get full text

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications by Passamonti, F, Rumi, E, Pietra, D, Elena, C, Boveri, E, Arcaini, L, Roncoroni, E, Astori, C, Merli, M, Boggi, S, Pascutto, C, Lazzarino, M, Cazzola, M

“…We studied the relationship between JAK2 (V617F) mutant allele burden and clinical phenotype, disease progression and survival in patients with polycythemia…”
Get full text

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients by Passamonti, Francesco, Rumi, Elisa, Arcaini, Luca, Boveri, Emanuela, Elena, Chiara, Pietra, Daniela, Boggi, Sabrina, Astori, Cesare, Bernasconi, Paolo, Varettoni, Marzia, Brusamolino, Ercole, Pascutto, Cristiana, Lazzarino, Mario

“…1 Division of Hematology and 2 Department of Surgical Pathology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy Correspondence:…”
Get full text

A sequence of immuno‐chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high‐dose chemotherapy and autotransplant is an effective 
and non‐toxic treatment for advanced follicular 
and mantle cell lymphoma by Lazzarino, M., Arcaini, L., Bernasconi, P., Alessandrino, E. P., Gargantini, L., Cairoli, R., Orlandi, E., Astori, C., Brusamolino, E., Pagnucco, G., Colombo, A. A., Calatroni, S., Iacona, I., Regazzi, M. B., Morra, E.

“…Options for relapsed/refractory indolent lymphoma include chemotherapy, immunotherapy and high‐dose therapy with autologous support. The best combination of…”
Get full text

Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radiotherapy : analysis of efficacy and long-term toxicity by BRUSAMOLINO, Ercole, LUNGHI, Francesca, BERNASCONI, Carlo, ORLANDI, Ester, ASTORI, Cesare, PASSAMONTI, Francesco, BARATE, Claudia, PAGNUCCO, Guido, BAIO, Ambrogia, FRANCHINI, Pietro, LAZZARINO, Mario

Get full text

Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma by CORSO, A, MANGIACAVALLI, S, TROLETTI, D, PASCUTTO, C, MORRA, E, LAZZARINO, M, NOSARI, A, CASTAGNOLA, C, ZAPPASODI, P, CAFRO, A. M, ASTORI, C, BONFICHI, M, VARETTONI, M, RUSCONI, C

“…From 2000 to 2004, 152 patients with multiple myeloma aged <or=65 years, enrolled in high-dose programs, were treated with two schedules of DCEP…”
Get full text

Peripheral intraneutrophil diplococci in a case of meningococcemia by Rumi, E, Astori, C, Casazza, A, Marone, P, Bonfichi, M

Get full text

Biochemical markers of bone disease in asymptomatic early stage multiple myeloma. A study on their role in identifying high risk patients by Corso, A, Arcaini, L, Mangiacavalli, S, Astori, C, Orlandi, E, Lorenzi, A, Passamonti, F, Klersy, C, Pascutto, C, Canevari-Sciorati, A, Lazzarino, M

“…Institute of Hematology, University of Pavia, Italy. a.corso@smatteo.pv.it BACKGROUND AND OBJECTIVES: Skeletal involvement is typical of multiple myeloma (MM)…”
Get full text

Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features by Lazzarino, M, Orlandi, E, Paulli, M, Boveri, E, Morra, E, Brusamolino, E, Kindl, S, Rosso, R, Astori, C, Buonanno, M C

“…To evaluate the clinical features of presentation, the morphologic and immunohistochemical pattern, the modality of spread, and the response to current…”
Get more information

Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma by Lazzarino, M., Orlandi, E., Montillo, M., Tedeschi, A., Pagnucco, G., Astori, C., Corso, A., Brusamolino, E., Simoncini, L., Morra, E., Bernasconi, C.

“…Purpose: Fludarabine phosphate is effective as a single agent in low-grade non-Hodgkin's lymphoma (NHL). Combined with other antineoplastic agents it enhances…”
Get full text

Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma : Correlation with tumor parameters and disease activity by LAZZARINO, M, ORLANDI, E, KLERSY, C, ASTORI, C, BRUSAMOLINO, E, CORSO, A, BELLIO, L, GARGANTINI, L, MORRA, E, BERNASCONI, C

“…CA 125 is a glycoprotein produced by epithelial ovarian tumors and by mesothelial cells; its levels also have been shown to be elevated in patients with…”
Get full text

Transient response of myeloma clone to pamidronate therapy by Corso, A, Astori, C, Orlandi, E, Zappasodi, P, Arcaini, L, Bernasconi, C

Get full text

Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin's lymphoma by Bernasconi, P, Orlandi, E, Cavigliano, P, Calatroni, S, Boni, M, Astori, C, Pagnucco, G, Giglio, S, Caresana, M, Lazzarino, M, Bernasconi, C

“…Divisione di Ematologia, Policlinico San Matteo IRCCS, piazzale Golgi 1, 27100 Pavia, Italy. We describe a 65-year old woman who developed a t(8;16)(p11;p13)…”
Get full text

Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival by Bernasconi, P, Alessandrino, E P, Boni, M, Bonfichi, M, Morra, E, Lazzarino, M, Campagnoli, C, Astori, C

“…One hundred eighty-eight unselected consecutive patients with "de novo" myelodysplastic syndrome (MDS) were studied cytogenetically. They were subclassified as…”
Get more information

Cytogenetic and FISH analyses in five patients with hypoplastic bone marrow by Bernasconi, P, Astori, C, Cavigliano, P M, Boni, M, Malcovati, L, Calatroni, S, Caresana, M, Bernasoconi, C

Get full text

Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma by Orlandi, E, Lazzarino, M, Bernasconi, P, Astori, C, Bernasconi, C

“…We report on two patients who developed a secondary acute myeloid leukemia (sAL) after treatment for non-Hodgkin's lymphoma (NHL) with regimens containing low…”
Get full text

A novel t(Y;11) translocation with MLL gene rearrangement in a case of acute myelomonocytic leukemia (AML-M4) by Bernasconi, P, Cavigliano, P M, Boni, M, Malcovati, L, Calatroni, S, Astori, C, Caresana, M, Bernasconi, C

Get full text

Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy by Brusamolino, E, Lazzarino, M, Orlandi, E, Canevari, A, Morra, E, Castelli, G, Alessandrino, E P, Pagnucco, G, Astori, C, Livraghi, A

“…Controversy still exists over the optimal management of early-stage Hodgkin's disease (HD); presentation features may have a different prognostic impact…”
Get more information

Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia by Rumi, Elisa, Bertozzi, Irene, Casetti, Ilaria C, Roncoroni, Elisa, Cavalloni, Chiara, Bellini, Marta, Sant'Antonio, Emanuela, Gotti, Manuel, Ferretti, Virginia V, Milanesi, Chiara, Peroni, Edoardo, Pietra, Daniela, Astori, Cesare, Randi, Maria Luigia, Cazzola, Mario

Get full text

Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients by RUMI, Elisa, PASSAMONTI, Francesco, ELENA, Chiara, PIETRA, Daniela, ARCAINI, Luca, ASTORI, Cesare, ZIBELLINI, Silvia, BOVERI, Emanuela, PASCUTTO, Cristiana, LAZZARINO, Mario

“…Within a cohort of 1,915 consecutive patients with myeloproliferative neoplasm followed for a median time of 5.2 years (range 0-33.3), we investigated the…”
Get full text